KELLSEY SENN: Open Payments
NPI 1407488893 · LEXINGTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$612 in 27 payments from 13 companies in 2025. Trend: 2023 $75 · 2024 $238 · 2025 $612
Food & beverage: $612
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 4 | $131 |
| GlaxoSmithKline, LLC. | 4 | $85 |
| AstraZeneca Pharmaceuticals LP | 4 | $76 |
| Genentech USA, Inc. | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Optinose US, Inc. | 3 | $48 |
| Galderma Laboratories, L.P. | 2 | $37 |
| Pharming Healthcare, Inc. | 1 | $29 |
| BioCryst US Sales Co., LLC | 1 | $28 |
| Amgen Inc. | 1 | $19 |
Products named: DUPIXENT, TEZSPIRE, NUCALA, Xolair, CUVITRU, Xhance, NEMLUVIO, RUCONEST.
Industry payments across SC — which companies pay providers there.
